Unknown PHASE2 INTERVENTIONAL 2-arm NCT04397497

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) (COMBAT-19)

A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)

Sponsor: Ospedale San Raffaele

Conditions ARDS, Human Acute Respiratory Failure Covid-19 Sars-CoV2 Viral Pneumonia

Interventions Mavrilimumab Placebo

Updated 6 times since 2020 Last updated: May 21, 2020 Started: May 22, 2020 Primary completion: Sep 22, 2020 Completion: Nov 22, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on ARDS, Human and Acute Respiratory Failure, this trial is ongoing. The trial is conducted by Ospedale San Raffaele and has accumulated 6 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Jun 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ospedale San Raffaele

Data source: Ospedale San Raffaele

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy
• San Donato, Italy